Physician profile
Shalimar Small
NPI 1023429685
$1,828.24
in general payments reported to CMS, 2019-2025
14 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $237 · 2021: $136 · 2022: $228 · 2023: $161 · 2024: $24.44 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $667.87 | 2019-2025 | Hydrus Microstent, Rocklatan |
| Allergan, INC. | $264.22 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $237.94 | 2019-2021 | |
| Biotissue Holdings INC. | $119.40 | 2021-2025 | |
| New World Medical,INC. | $106.47 | 2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Clearpath |
| Sun Pharmaceutical Industries INC. | $86.98 | 2019-2021 | |
| Abbvie INC. | $86.52 | 2022-2025 | Durysta |
| Johnson & Johnson Surgical Vision, INC. | $69.55 | 2023 | Tecnis Simplicity, Catalys System |
| Bausch & Lomb Americas INC. | $61.91 | 2022-2025 | Miebo, Vyzulta |
| Aerie Pharmaceuticals, INC. | $42.89 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $29.98 | 2023 | Acthar |
| Dompe US, INC. | $24.44 | 2024 | Oxervate |
| Genentech USA, INC. | $18.61 | 2022 | |
| Eyevance Pharmaceuticals LLC | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shalimar Small listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.